Insights / Resource Center
Resources
Events
AMM Ascent 2026
October 28-30, Primrose Bio presents and exhibits at AMM Ascent, Coronado, CA.
PEGS Europe 2026: Protein & Antibody Engineering Summit
November 16-19, Primrose Bio presents and exhibits at PEGS EU, Lisbon, Portugal.
14th International mRNA Health Conference 2026
November 17-19, Primrose Bio presents and exhibits at the mRNA Conference, Boston, MA.
Presentations & Webinars
How Polymerase Selection Improves IVT Outcomes
Self-amplifying RNA (saRNA) manufacturing places stringent demands on in vitro transcription (IVT), particularly for long templates where polymerase processivity, transcript integrity, capping...
Streamlining Discovery and Development for ncAA Incorporation and Extracellular Protein Production
Streamlining Discovery and Development Workflows Using Engineered P. fluorescens Strains for ncAA Incorporation and Extracellular Protein Production Diane Retallack, President & COO, Primrose...
Strategies To Reduce mRNA Manufacturing Costs
Manufacturing costs are one of the most pressing challenges facing teams working to scale RNA therapeutic and vaccine pipelines. In vitro transcription, or IVT, relies on several central raw...
Double Stranded RNA Formation And How RNA Polymerase Choice Can Reduce It
Double-stranded RNA is one of those stubborn byproducts that can quietly inflate downstream purification costs and compromise mRNA product quality. In this presentation, Patrik Engström, Principal...
Accelerating Antibody Screening with a Scalable Protein Expression Platform
Diane Retallack, President & COO, Primrose Bio at PepTalk: The Protein Science and Production Week at San Diego, CA P. fluorescens-based Pfenex Expression Technology® transforms protein...
A Rapid, Robust Solution for Accelerating Antibody Screening
A Rapid, Robust Solution for Accelerating Antibody Screening: P. fluorescens-based Pfenex Expression Technology® transforms protein production through combinatorial screening to identify robust...
Scientific Posters
Presented at the World Vaccine Congress 2026: Extracellular Secretion and Non-canonical Amino Acid (ncAA) Incorporation: New Capabilities Supporting Conjugate Vaccine Discovery and Development
ABSTRACT: Efficient production of vaccine carrier proteins and antigens is paramount to ensuring access to affordable conjugate vaccines. Streamlined conjugation technologies improve product quality...
Presented at the BioProcess International US West (BPI West) 2026: Engineered Fusion Partners Enabling HighYield Recombinant Peptide Production
ABSTRACT: Peptide therapeutics are a fast-growing class of medicines, but traditional solid phase peptide synthesis (SPPS) has limitations in cost, scalability, and environmental impact. Pfenex...
Presented at PepTalk The Protein Science and Production Week: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs As an example of the workflow, an...
Case Studies
Pfenex
Fusion-Enabled Biosimilar Peptide Teriparatide Expression
Teriparatide, a recombinant PTH (1-34) fragment used in osteoporosis therapy, is a short peptide that can be difficult to express and recover efficiently.
Pfenex
Development of an Oncology VHH-ADC Candidate via Site-Specific Non-Canonical Amino Acid Conjugation
Incorporate a non-canonical amino acid (ncAA) pAzF, into a VHH antibody for ADC enhancement, PET771
Pfenex
Pfast™ Lead Identification and Optimization Supporting Computational Drug Discovery Technology
Al generated, humanized Fab from partner required production and binding assessment
Pfenex
Rapid Assessment of Fab-VHH Expression Application of the Pfast™ Program for Early-Stage Titer and Activity Screening
Development of a bi-specific antibody derivative: a Fab-VHH fusion
Pfenex
Recombinant Erwinia Asparaginase Production
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Lymphoblastic lymphoma (LBL) is a rare, fast-growing, aggressive subtype of non-Hodgkin’s lymphoma most often seen in teenagers and young adults.
Pfenex
Production of disulfide-rich cow knob domain antibodies: picobodies™
About 10% of cow antibodies have exceptionally long heavy chain CDR3 regions, including a stalk and knob region.
Pfenex
Multimeric vhh nanobody expression
Pfenex
Fab antibody fragment titer improvement
Anti-IL-4 Conjugate Vaccine Prepared with PeliCRM197 is More Immunogenic than KLH Analog
Comparable Immunogenicity Observed in Peptides Coupled to PeliCRM197 and KLH in a Murine Model
In this case study, 3 peptides (peptides #5, #6, and #7) directed to one therapeutic target were conjugated to either CRM197 (a non-toxic diphtheria toxin mutant) produced with Pfenex Expression Technology® or to KLH (keyhole limpet hemocyanin).
Articles
When Your Expression System Isn’t Cooperating With Your Protein
Most biologics teams do not begin development by choosing an expression host from a blank slate.
Strain Engineering & Process Development: A Commercially Proven Platform for Biopharmaceutical Manufacturing
A number of factors contribute to delivering a robust, highly productive, and reliable process for manufacturing a therapeutic protein.
Success Stories
Manufacturing of RYLAZE utilizes Pfenex Expression Technology
Hear from the senior director for the biologics development team at Jazz Pharmaceuticals about the RYLAZE manufacturing process.